Table 1. The Demographic and Clinical Features of Patients Subjected to Detection and Quantification of Y93 Wild and Y93H Mutant HCV Strains by Real-Time PCR Using Cycling Probe Mixtures.
| All patients (n = 332) | Quantified through real-time PCR using cycling probe mixutures (n = 295) | ||
| Those detected of Y93 Wild Strain (n = 237) | Those detected of Y93H Mutant Strain (n = 58) | ||
| Age | 67.0±11.3a | 66.9±11.7 | 67.7±10.4 |
| Men: Women | 144: 188b | 106: 131 | 18: 40 |
| Previous therapy (Naïve: Relapser: No-responder: BTH1) | 186: 72: 69: 5b | 130: 49: 53: 5 | 37: 14: 7: 0 |
| ALT (IU/L) | 41.6±32.4a | 40.6±30.3 | 41.5±35.9 |
| Albumin (g/dL) | 3.9±0.5a | 3.9±0.5 | 4.0±0.5 |
| γGTP (IU/L) | 40.6±55.7a | 40.6±59.3 | 29.9±26.0 |
| Creatinine (mg/dL) | 0.84±0.10a | 0.83±0.94 | 0.79±0.99 |
| Total Cholesterol (mg/dL) | 156.9±34.3a | 155.8±35.4 | 161.0±30.1 |
| Total Bilirubin (mg/dL) | 0.8±0.5a | 0.82±0.53 | 0.78±0.36 |
| α-fetoprotein (ng/mL) | 38.6±354.4a | 49.7±419.3 | 8.0±11.0 |
| HCV-RNA (Log copies/mL) | 6.4±1.1a | 6.3±1.0* | 6.7±0.8 |
| White blood cell (103/mL) | 4.73±1.75a | 4.68±1.81 | 4.94±1.57 |
| Hemoglobin (g/dL) | 13.1±2.0a | 13.0±2.1 | 13.1±1.8 |
| Platelets (103/mm3) | 148±61a | 148±62 | 153±60 |
| HCC (positive: negative) | 57: 275b | 41: 196** | 4: 54 |
1
BTH indicates viral breakthrough during the previous therapy.
a
mean ± SD,
b
Number of patients
*p<0.05 by t-test,
**p<0.05 by Fisher's exact test vs Those detected of Y93H Mutant Strain.